Has Romy Cabacungan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $463,840 in general payments to Romy Cabacungan, MD across 1,351 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Romy Cabacungan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Romy Cabacungan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Romy Cabacungan, MD

Rheumatology · Tucson, AZNPI 1417190828

Payments from drug & device makers

$463,840in general payments, 2019–2025

Across 1,351 payments — averaging $343.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$146K
Amgen$126K
Eli Lilly$88K
Argenx US, Inc.$47K
Genentech, Inc.$28K
Janssen Research & Development, LLC$16K
plus $13K from 41 others

$29,101in research payments, 2019–2025

Across 2 payments — averaging $14,550 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$29K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	300	$145,880
Amgen(2 entities)	337	$126,328
Eli Lilly	4	$87,559
Argenx US, Inc.	45	$46,780
Genentech, Inc.	3	$28,300
Janssen Research & Development, LLC	2	$15,979
UCB, Inc.	108	$2,322
Pfizer	131	$1,822
GSK	58	$995
AstraZeneca(2 entities)	35	$944
Sanofi	31	$881
Lilly USA, LLC	39	$825
E.r. Squibb & Sons, L.L.C.	38	$667
Johnson & Johnson(2 entities)	34	$577
Novartis	29	$539
Radius Health, Inc.	26	$522
Organon	18	$366
Mallinckrodt Hospital Products Inc.	12	$339
Genentech USA, Inc.	14	$257
Sobi, Inc	10	$247
Boehringer Ingelheim	10	$225
Janssen Scientific Affairs, LLC	2	$204
Bristol Myers Squibb	10	$153
Ferring Pharmaceuticals Inc.	8	$148
Bioventus LLC	5	$108
Kyowa Kirin, Inc.	4	$102
Mallinckrodt Enterprises LLC	4	$73
Octapharma USA, Inc.	2	$69
Pacira Therapeutics, Inc.	3	$60
Teva Pharmaceuticals USA, Inc.	3	$51
Viiv Healthcare Company	2	$51
Actelion Pharmaceuticals US, Inc.	3	$51
Hikma Pharmaceuticals USA	3	$48
Aurinia Pharma U.S., Inc.	3	$45
Kiniksa Pharmaceuticals International, PLC	1	$40
Kiniksa Pharmaceuticals, Ltd.	2	$34
Fresenius Kabi USA, LLC	1	$31
Biogen	1	$29
Merck	2	$26
Celltrion USA Inc.	1	$26
Alvogen Inc	1	$25
United Therapeutics Corporation	1	$25
Tersera Therapeutics LLC	1	$21
ANI Pharmaceuticals, Inc.	1	$18
Abbott	1	$17
Ultragenyx Pharmaceutical Inc.	1	$16
Oxford Immunotec USA Inc	1	$16

How this compares

$463,840 in reported general payments places this provider in the 80th percentile of 102 rheumatology providers in Arizona.

See all rheumatology providers in Arizona →

Medicare billing

Part B allowed, 2024

$2,194,799

Medicare patients

593

Services billed

171,761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Tucson

Jeffrey LoomerTucson$1.9M
Jawad BilalTucson$185K
Chian KwohTucson$166K
Dominick SudanoTucson$145K
Barbara BodeTucson$111K
Michael MaricicTucson$110K
Augusto PosadasTucson$81K
Ernest VinaTucson$48K
Ulker TokTucson$20K
Jeffrey LisseTucson$13K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →